Centrient Pharmaceuticals International B.V.

Tweet this page
<
2020
2021
2022
2023
2024
>
Registration as it was on 16 Dec 2024
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

10,000€

Financial year: Jan 2023 - Dec 2023

Lobbyists (Full time equivalent)

0.1 Fte (1)

Lobbyists with EP accreditation

0

High-level Commission meetings

3

Lobbying Costs over the years

  • Info

    Centrient Pharmaceuticals International B.V.

    EU Transparency Register

    494574538937-86 First registered on 13 Jul 2020

    Goals / Remit

    Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs).

    We are a pharmaceutical company with a mission to improve lives by being at the centre of sustainable and accessible healthcare.

    Main EU files targeted

    EU Pharmaceutical Strategy, EU Healthcare Policy, EU Industrial Policy, EU Environmental Policy (Green Deal), EU Trade Policy, AMR Policy

    Address

    Head Office
    Weena 798 E-F
    Rotterdam 3014DA
    NETHERLANDS
    EU Office
    Weena 798 E-F
    Rotterdam 3014DA
    NETHERLANDS

    Website

  • People

    Total lobbyists declared

    1

    Employment timeLobbyists
    10%1

    Lobbyists (Full time equivalent)

    0.1

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    AMR Industry Alliance

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2023 - Dec 2023

    Lobbying costs for closed financial year

    10,000€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    None declared

    Closed year Costs

    0€ - 10,000€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    N/A

    Communication activities

    Not applicable this year

    Other activities

    None declared

  • Meetings

    Meetings

    3 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

    • Date 30 Jun 2022 Location Santa Perpètua de Mogoda
      Subject Pharmaceutical Strategy
      Cabinet Cabinet of Vice-President Margaritis Schinas
      Portfolio Promoting the European Way of Life
      Attending
      • Maria Luisa Llano Cardenal (Cabinet member)
      • Margaritis Schinas (Vice-President)
    • Date 14 Jan 2022 Location Videoconference
      Subject Security of supply of pharmaceutical ingredients and intermediates
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Maurits-Jan Prinz (Cabinet member)
    • Date 15 Sep 2020 Location Videoconference
      Subject Strengthening the EU’s production capacity for live-saving pharmaceuticals.
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Eszter Batta (Cabinet member)
Download this datacard